A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor α expressed from an adenovirus vector induces an antitumor response with reduced toxicity

Cancer Gene Therapy

Volumn 6, Issue 5, 1999, Pages 465-474

  Marr, Robert A ^a   Hitt, Mary ^a   Gauldie, Jack ^a   Muller, William J ^a   Graham, Frank L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus; Gene therapy; Immunotherapy; Tumor necrosis factor receptor; Tumor necrosis factor ; Tumor therapy

Indexed keywords

LEUKOCYTE ANTIGEN; PRIMER DNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADENOVIRUS; ANIMAL; ARTICLE; CELL DIVISION; EXPERIMENTAL NEOPLASM; GENE VECTOR; GENETICS; IMMUNOLOGY; MOUSE; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TRANSGENIC MOUSE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD; BASE SEQUENCE; CELL DIVISION; DNA PRIMERS; GENETIC VECTORS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MUTATION; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033190968     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700068     Document Type: Article

References (41)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975; 72:3666-3670.
2. Fiers W. Tumor necrosis factor: characterization at the molecular, cellular, and in vivo level. FEBS Lett. 1991;285: 199-212.
3. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Jr, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA. 1991;88:9292-9296.
4. Vilcek J, Lee TH. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266:7313-7316.
5. Sarraf CE. Tumour necrosis factor and cell death in tumours, Int J Oncol. 1994;5:1333-1339.
6. Benigni F, Faggioni R, Sironi M, et al. TNF receptor p55 plays a major role in centrally mediated increases of serum IL-6 and corticosterone after intracerebroventricular injection of TNF. J Immunol. 1996;157:5563-5568.
7. Vandenabeele P, Declerq W, Vercammen D, et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med. 1992;176:1015-1024.
8. Lewis M, Tartaglia LA, Bennett LA, et al. Cloning and expression of a cDNA for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA. 1991;88:2830-2834.
9. Ranges GE, Bombara MP, Aiyer RA, Rice GG, Palladino MA, Jr. Tumor necrosis factor-α as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action. J Immunol. 1989;142:1203-1208.
10. Bluethmann H, Rothe J, Schultze N, Tkachuk M, Koebel P. Establishment of the role of IL-6 and TNF receptor 1 using gene knockout mice. J Leukoc Biol. 1994;56:565-570.
11. Erickson SL, de Sauvage FJ, Kikly K, et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994;372:560-563.
12. Sheehan KCF, Pinkard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med. 1995;181:607-617.
13. Loetscher H, Stueber D, Banner D, Mackay F, Lessauer W. Human tumor necrosis factor α (TNFα) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem. 1993;268:26350-26357.
14. Van Ostade X, Vandenabeele P, Tavernier J, Fiers W. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. Eur J Biochem. 1994;220:771-779.
15. Fidler IJ. Biological behaviour of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 1975;35:218-234.
16. Graham FL, Smiley J, Russel WC, Nairn R. Characterization of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-72.
17. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther. 1996;7:333-342.
18. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyoma virus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954-961.
19. Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA. 1997;94:10889-10894.
20. Higuchi R. Recombinant PCR. In: Innis MA, Gelfand DH, Sninski JJ, White TJ, cds. PCR Protocols: A Guide to Methods and Applications. San Diego: Academic Press; 1990:177-180.
21. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human and murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol. 1997;78:1653-1661.
22. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
23. Hitt M, Bett A, Addison C, Prevec L, Graham FL. Techniques for human adenovirus vector construction and characterization. In: Adolph KW, ed. Viral Gene Techniques: Methods in Molecular Genetics. San Diego: Academic Press; 1995:13-30.
24. Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL. Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFα. Gene Ther. 1997;4:1181-1188.
25. Marr RA, Hitt M, Muller WJ, Gauldie J, Graham FL. Tumour therapy in mice using adenovirus vectors expressing human TNFα. Int J Oncol 1998;12:509-515.
26. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 1997;4:1069-1076.
27. Paleolog EM, Delasalle AAJ, Buurman WA, Feldman M. Functional activities of receptors for tumor necrosis factor-α on human vascular endothelial cells. Blood. 1994;84: 2578-2590.
28. Palladino MA, Jr, Refaat SM, Kramer SM, et al. Characterization of the antitumor activities of human TNF-α and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol. 1987;138:4023-4032.
29. Trepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:153-164.
30. Marincola FM, Ettinghausen S, Cohen PA, et al. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α. J Immunol. 1994; 152:3501-3513.
31. Welborn MB, III, Van Zee K, Edwards PD, et al. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J Exp Med. 1996;184:165-171.
32. Glickstein LJ, Huber BT. Karoushi-death by overwork in the immune system. J Immunol. 1995;155:522-524.
33. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348-351.
34. + T cell anergy. Clin Exp Immunol. 1997;109:41-46.
35. 2. J Immunol 1994;153:1674-1686.
36. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994;94:749-760.
37. Barbara JAJ, Smith WB, Gamble JR, et al. Dissociation of TNF-α cytotoxicity and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-α mutants. EMBO J. 1994;13:843-850.
38. Van der Poll T, Jansen PM, Van Zee KJ, et al. Tumor necrosis factor-α induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood. 1996;88:922-927.
39. Prober JS. Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. In: Bock G, Marsh J, eds. Tumour Necrosis Factor and Related Cytotoxins. Chichester (Ciba Foundation Symposium). New York: Wiley; 1984:170-185.
40. Clauss M, Ryan J, Stern D. Modulation of endothelial cell haemostatic properties by TNF: insights into the role of the endothelium in the host response to inflammatory stimuli. In: Beutler D, ed. Tumour Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York: Raven Press; 1992:49-64.
41. Denekamp J. Review article: angiogenesis, neovascular proliferation, and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993;66:181-196.